Targeting of erbB3 receptor to overcome resistance in cancer treatment

The erbB receptors, including the epidermal growth factor receptor (EGFR), erbB2 (also known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated in a wide variety of human cancers. They are excellent targets for selective anti-cancer therapies because of their transmem...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jian, Lyu, Hui, Huang, Jingcao, Liu, Bolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022415/
https://www.ncbi.nlm.nih.gov/pubmed/24886126
http://dx.doi.org/10.1186/1476-4598-13-105
_version_ 1782316402649071616
author Ma, Jian
Lyu, Hui
Huang, Jingcao
Liu, Bolin
author_facet Ma, Jian
Lyu, Hui
Huang, Jingcao
Liu, Bolin
author_sort Ma, Jian
collection PubMed
description The erbB receptors, including the epidermal growth factor receptor (EGFR), erbB2 (also known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated in a wide variety of human cancers. They are excellent targets for selective anti-cancer therapies because of their transmembrane location and pro-oncogenic activity. While several therapeutic agents against erbB2 and/or EGFR have been used in the treatment of human cancers with efficacy, there has been relatively less emphasis on erbB3 as a molecular target. Elevated expression of erbB3 is frequently observed in various malignancies, where it promotes tumor progression via interactions with other receptor tyrosine kinases (RTKs) due to its lack of or weak intrinsic kinase activity. Studies on the underlying mechanisms implicate erbB3 as a major cause of treatment failure in cancer therapy, mainly through activation of the PI-3 K/Akt, MEK/MAPK, and Jak/Stat signaling pathways as well as Src kinase. It is believed that inhibition of erbB3 signaling may be required to overcome therapeutic resistance and effectively treat cancers. To date, no erbB3-targeted therapy has been approved for cancer treatment. Targeting of erbB3 receptor with a monoclonal antibody (Ab) is the only strategy currently under preclinical study and clinical evaluation. In this review, we focus on the role of erbB3-initiated signaling in the development of cancer drug resistance and discuss the latest advances in identifying therapeutic strategies inactivating erbB3 to overcome the resistance and enhance efficacy of cancer therapeutics.
format Online
Article
Text
id pubmed-4022415
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40224152014-05-16 Targeting of erbB3 receptor to overcome resistance in cancer treatment Ma, Jian Lyu, Hui Huang, Jingcao Liu, Bolin Mol Cancer Review The erbB receptors, including the epidermal growth factor receptor (EGFR), erbB2 (also known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated in a wide variety of human cancers. They are excellent targets for selective anti-cancer therapies because of their transmembrane location and pro-oncogenic activity. While several therapeutic agents against erbB2 and/or EGFR have been used in the treatment of human cancers with efficacy, there has been relatively less emphasis on erbB3 as a molecular target. Elevated expression of erbB3 is frequently observed in various malignancies, where it promotes tumor progression via interactions with other receptor tyrosine kinases (RTKs) due to its lack of or weak intrinsic kinase activity. Studies on the underlying mechanisms implicate erbB3 as a major cause of treatment failure in cancer therapy, mainly through activation of the PI-3 K/Akt, MEK/MAPK, and Jak/Stat signaling pathways as well as Src kinase. It is believed that inhibition of erbB3 signaling may be required to overcome therapeutic resistance and effectively treat cancers. To date, no erbB3-targeted therapy has been approved for cancer treatment. Targeting of erbB3 receptor with a monoclonal antibody (Ab) is the only strategy currently under preclinical study and clinical evaluation. In this review, we focus on the role of erbB3-initiated signaling in the development of cancer drug resistance and discuss the latest advances in identifying therapeutic strategies inactivating erbB3 to overcome the resistance and enhance efficacy of cancer therapeutics. BioMed Central 2014-05-08 /pmc/articles/PMC4022415/ /pubmed/24886126 http://dx.doi.org/10.1186/1476-4598-13-105 Text en Copyright © 2014 Ma et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Ma, Jian
Lyu, Hui
Huang, Jingcao
Liu, Bolin
Targeting of erbB3 receptor to overcome resistance in cancer treatment
title Targeting of erbB3 receptor to overcome resistance in cancer treatment
title_full Targeting of erbB3 receptor to overcome resistance in cancer treatment
title_fullStr Targeting of erbB3 receptor to overcome resistance in cancer treatment
title_full_unstemmed Targeting of erbB3 receptor to overcome resistance in cancer treatment
title_short Targeting of erbB3 receptor to overcome resistance in cancer treatment
title_sort targeting of erbb3 receptor to overcome resistance in cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022415/
https://www.ncbi.nlm.nih.gov/pubmed/24886126
http://dx.doi.org/10.1186/1476-4598-13-105
work_keys_str_mv AT majian targetingoferbb3receptortoovercomeresistanceincancertreatment
AT lyuhui targetingoferbb3receptortoovercomeresistanceincancertreatment
AT huangjingcao targetingoferbb3receptortoovercomeresistanceincancertreatment
AT liubolin targetingoferbb3receptortoovercomeresistanceincancertreatment